SG Americas Securities LLC Sells 35,344 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS)

SG Americas Securities LLC lowered its holdings in shares of Coherus BioSciences, Inc. (NASDAQ:CHRSGet Rating) by 44.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 43,895 shares of the biotechnology company’s stock after selling 35,344 shares during the quarter. SG Americas Securities LLC owned 0.06% of Coherus BioSciences worth $567,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of CHRS. Point72 Hong Kong Ltd bought a new position in Coherus BioSciences during the fourth quarter valued at $119,000. Teacher Retirement System of Texas purchased a new stake in shares of Coherus BioSciences in the fourth quarter valued at $191,000. Inspire Investing LLC purchased a new stake in shares of Coherus BioSciences in the first quarter valued at $234,000. Natixis Advisors L.P. raised its stake in shares of Coherus BioSciences by 13.0% in the fourth quarter. Natixis Advisors L.P. now owns 16,773 shares of the biotechnology company’s stock valued at $268,000 after acquiring an additional 1,933 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in shares of Coherus BioSciences in the fourth quarter valued at $284,000. Institutional investors own 97.85% of the company’s stock.

Coherus BioSciences Trading Up 0.4 %

NASDAQ CHRS opened at $10.06 on Thursday. The company has a debt-to-equity ratio of 33.47, a quick ratio of 3.09 and a current ratio of 3.33. The company has a market capitalization of $778.88 million, a price-to-earnings ratio of -3.68 and a beta of 1.19. The company’s 50-day simple moving average is $7.68 and its two-hundred day simple moving average is $10.03. Coherus BioSciences, Inc. has a one year low of $5.60 and a one year high of $19.32.

Coherus BioSciences (NASDAQ:CHRSGet Rating) last posted its earnings results on Thursday, May 5th. The biotechnology company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.44). The business had revenue of $60.12 million for the quarter, compared to analysts’ expectations of $68.07 million. Coherus BioSciences had a negative net margin of 69.24% and a negative return on equity of 211.68%. Equities analysts forecast that Coherus BioSciences, Inc. will post -3.77 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on CHRS shares. Barclays reduced their target price on shares of Coherus BioSciences from $20.00 to $15.00 in a research note on Monday, May 9th. UBS Group started coverage on shares of Coherus BioSciences in a research note on Monday, June 13th. They issued a “neutral” rating and a $7.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Coherus BioSciences in a research note on Tuesday, May 3rd. Finally, Mizuho reduced their price target on shares of Coherus BioSciences from $30.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, May 20th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.00.

Coherus BioSciences Profile

(Get Rating)

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis.

Read More

Institutional Ownership by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Want More Great Investing Ideas?

Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.